- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03447756
Titration Study of ABX-1431
A Randomized, Placebo-Controlled, Optimized Titration Study of ABX-1431 in Adult Patients With Peripheral Neuropathic Pain
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a double-blind, placebo-controlled, optimized titration study of ABX-1431 HCl. The study will explore whether patients experiencing ABX-1431-related CNS AE accommodate or become tolerant to them with continued dosing. The efficacy of ABX-1431 in treating neuropathic pain will be assessed by the change from baseline in pain intensity scores using numerical rating scale (NRS-11).
All patients will undergo a screening visit for enrollment criteria. Eligible patients will be treated with daily medication for 28 days which will include some treatment with placebo and some treatment with ABX-1431 HCl. Patients will record their daily average pain using a paper numerical rating scale (NRS-11).
This study will enroll up to 32 patients with peripheral neuropathic pain due to one of the four following diagnostic groups: post-herpetic neuralgia, diabetic peripheral neuropathy, small fiber neuropathy or post-traumatic neuropathic pain.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Chisinau, Moldova, Republic of, MD-2025
- Republican Clinical Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Patient is a male or female over the age of 18 years of age at the Screening Visit.
Patient has a peripheral neuropathic pain in one of the following diagnostic groups that is persistent for > 3 months
- Post-herpetic neuralgia
- Diabetic peripheral neuropathy
- Small fiber neuropathy
- Post-traumatic neuropathic pain
- Patient's median NRS-11 pain intensity score must be ≥ 4 during the baseline period
- If a patient enters the trial on daily background neuropathic pain medications, then the patient must be on stable dose of medications for at least 30 days before enrollment and throughout the study.
- Patient is able to understand and comply with the protocol procedures for the entire trial and must give written informed consent.
- Men and Women must agree to a medically approved contraceptive regimen.
Key Exclusion Criteria:
- Patient is taking potent cytochrome P450 3A4/5 inducers or inhibitors
- Patient has received injection therapies (e.g., botulinum toxin, anesthetic or nerve block) or transcutaneous electrical stimulation to control pain in the past 60 days
- Patient has evidence of alcohol, drug or chemical abuse in the year before the Screening Visit.
- Patient is a lactating or pregnant female or a female who intends to become pregnant within 90 days following the last dose of investigational product.
- Patient has specific laboratory abnormalities
Other protocol-defined inclusion/exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ABX-1431
One or more oral capsules containing 2 mg or 10 mg or 50 mg of ABX-1431 HCl or matching placebo are administered daily to enrolled patients.
Patients will undergo a blinded dose escalation.
All patients will receive placebo on some days to assess safety and neuropathic pain.
Patients will undergo an optimized titration of ABX-1431 HCl with the daily dose between 8 mg and 24 mg of ABX-1431.
Each patients dose will be determined by the Investigator based on assessment of adverse events.
|
Capsules of either 2mg, 10mg, or 50mg
|
Placebo Comparator: Placebo oral capsule
One or more oral capsules containing placebo are administered daily to enrolled patients.
Patients will undergo a blinded dose escalation.
All patients will receive placebo on some days to assess safety and neuropathic pain.
Patients will undergo an optimized titration of placebo.
Each patients dose will be determined by the Investigator based on assessment of adverse events.
|
placebo to match
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identify a titration regimen of ABX-1431
Time Frame: 28 days
|
The number of patients unable to continue due to central nervous system (CNS) adverse events (AEs) while exceeding mean plasma ABX-1431 AUC_0-24 of 190 ng*hr/ml or inhibiting 2-arachidonoylglycerol (2-AG) hydrolysis in peripheral blood mononuclear cells (PBMC) by more than 62% time-weighted inhibition over 24-hours.
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tolerance to ABX-1431 related CNS AEs determined by whether or not AEs resolve with continued dosing
Time Frame: 28 days
|
28 days
|
|
Numerical Rating Scale (NRS-11)
Time Frame: 20 days
|
Change from Baseline in Pain Scores on the Numerical Rating Scale-11 (NRS-11) at 20 days.
|
20 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Vitale Lisnic, PhD, Arensia Exploratory Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ABX-1431_PN014
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Peripheral Neuropathy
-
Pamlab, L.L.C.HealthCore, Inc.CompletedDiabetic Peripheral Neuropathy (DPN)United States
-
Riphah International UniversityRecruitingDiabetic Peripheral Neuropathy (DPN)Pakistan
-
Tanta UniversityCompletedDiabetic Neuropathies | Diabetic Peripheral Neuropathy | Painful Diabetic Neuropathy | Autonomic Neuropathy | Diabetic Polyneuropathy | Small Fiber NeuropathyEgypt
-
Wuhan Central HospitalWuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd., Hubei, China; Wuhan...RecruitingDiabetic Peripheral Neuropathy Type 2China
-
University of PlymouthNot yet recruitingDiabetic Peripheral Neuropathy | Painful Diabetic Neuropathy
-
Tanta UniversityActive, not recruiting
-
October 6 UniversityCompletedDiabetic Neuropathy PeripheralEgypt
-
Fengmei LianPeking Union Medical College Hospital; Huashan Hospital; Chengdu University of... and other collaboratorsUnknownDiabetic Peripheral Neuropathy Type 2China
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.UnknownDiabetic Peripheral Neuropathy
-
Hawler Medical UniversityUnknownDiabetic Peripheral NeuropathyIraq
Clinical Trials on ABX-1431
-
Abide TherapeuticsCogState Ltd.; FGK Clinical Research GmbH; BASi (Bioanalytical Systems, Inc.)CompletedTourette Syndrome | Motor Tic DisorderGermany, Poland, Spain
-
Abide TherapeuticsUniversity of OxfordCompleted
-
Abide TherapeuticsTerminated
-
Abide TherapeuticsCompletedMultiple Sclerosis | Neuromyelitis Optica Spectrum Disorder | Transverse Myelitis | Longitudinally Extensive Transverse MyelitisUnited Kingdom
-
Abide TherapeuticsCompletedTourette Syndrome | Chronic Motor Tic DisorderGermany
-
Abalonex, LLCNot yet recruitingTraumatic Brain Injury | Cerebral Edema
-
AmgenCompletedNeoplasm Metastasis | Lung Cancer | Non-small Cell Lung Cancer
-
Eben RosenthalNational Cancer Institute (NCI)RecruitingPancreatic AdenocarcinomaUnited States
-
AbgenixImmunex CorporationCompletedProstate CancerUnited States